Sartorius Stedim Cellca GmbH

Sartorius Stedim Cellca is a leading provider of cell line and upstream process development services for large-scale protein production of biopharmaceuticals in mammalian (CHO) cells.
Competitive technology platform:
Based on its in-depth expertise, know-how and intellectual property, Cellca has established a unique technology platform, which is one of the most competitive systems available. It is characterized by high efficiency regarding quality, quantity and short development time, robustness and direct process scalability. So, customers and partners benefit from reduced cost of goods, reduced risks and a faster time-to-clinic / market.
Products and services:
Cellca offers the following products and services:
• Fee for service for Cell line & process development
• Technology Platform Licensing
• Media
Benefits:
• Speed:Within 4-6 months Cellca can deliver high-titer research cell bank starting
from DNA. 

• Performance: 95 % of our developed cell lines deliver protein titers exceeding 3
g/L in a 12-14 day standard fedbatch process. 

• Scalability: Processes can be easily transferred and scaled-up to a range of
bioreactors up to 1000L. 

• Track record: More than 40 successfully completed projects. 

• Customer focus: Committed project teams and dedicated client manager’s make it
their purpose to deliver service excellence and meet our 
 clients’ requirements.